Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
Letter to stakeholders regarding the requirements to provide results for authorized clinical trials in EudraCT
– European Medicines Agency; European Commission; Heads of Medicines Agencies
In a joint letter, the EMA, EC, and HMA urge sponsors to publish all clinical trial results. These regulators note that following current requirements is essential to protect public health and encourage innovation.
Read the full letter here
Score! ‘Good Pharma’ ranking finds uptick in new drug data sharing and clinical trial transparency
In its third edition, the ‘Good Pharma’ scorecard rankings—compiled by Bioethics International—finds that big pharma companies are sharing more clinical trial results data. The research found that 95% of patient trial results are publicly available within six months of FDA approval.
Read the article by Beth Snyder Bulik on FiercePharma
Event spotlight: ExL disclosure and transparency for clinical data summit (August 14-15)
ExL’s Third Disclosure and Transparency for Clinical Data Summit highlights data disclosure compliance, urging collaboration between the life science and clinical data transparency industries. Attendees will learn about commercial values and ethical responsibilities when executing national and global data transparency.
Visit ExL to register for this event